Fda Approves A New Generic Valsartan

Brand invoice price changes accounted for $26.3 billion in spending, contributing 8.2% to overall growth in 2014. Invoice price increases on protected brands averaged about 13.5%, but after adjusting for rebates and discounts, the net price increase is estimated to have been $10.3 billion, or 3.1% of total spending growth. Medicine spending rose by 13.1% and per capita spending https://diovan.live/ increased by 10.3%, which was the largest increase seen since 2001. Nominal spending totaled $373.9 billion in 2014 compared with $329.2 billion in 2013. Valsartan blocks the actions of angiotensin II, which include constricting blood vessels and activating aldosterone, to reduce blood pressure. The drug binds to angiotensin type I receptors , working as an antagonist.